

Fax completed form to: (855) 840-1678 If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

Tzield (teplizumab-mzwv)

PHYSICIAN INFORMATION			PATIENT INFORMATION					
* Physician's Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this					
Specialty:	* DEA, NPI or	TIN:	form are completed.*					
Office Contact Person:			* Patient Name:					
Office Phone:			* Cigna ID: * Dat			* Date of	Birth:	
Office Fax:			* Patient Street Address:					
Office Street Address:			City		State Zip			
City S	State	Zip	Patient Phone:	,				
Urgency: Standard Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)								
Medication requested: 🗌 T	ICD10:							
Directions for use:	or use: Dose:			ity: Duration of therapy:				
Is this a new start or continuation of therapy?.			tart of therapy					
This drug REQUIRES suppor			answers, includi	ing chart notes	s, lab/test	results, e	tc.	
Where will this medication be obtained? Accredo Specialty Pharmacy** Hospital Outpatient Retail pharmacy Other (please specify):			 Home Health / Home Infusion vendor Physician's office stock (billing on a medical claim form) **Cigna's nationally preferred specialty pharmacy 					
**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557								
Facility and/or doctor dispe	nsing and ad	ministering	medication:					
Facility Name: State: Address (City, State, Zip Code):			Tax ID#:					
Where will this drug be administered? Patient's Home Hospital Outpatient			Physician's OfficeOther (please specify):					
NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.								
Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? Yes No (provide medical necessity rationale):								
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?								
What is the patient's diagno to delay the onset of Stage 3 other (please specify):			nt?					

Clinical Information:							
Does the patient have documentation of ANY of the following type 1 diabetes-related autoantibodies on at least two s occasions: (a) anti-glutamic acid decarboxylase 65; (b) anti-islet antigen-2; (c) islet-cell autoantibody; (d) micro insulin transporter 8? Yes, to anti-glutamic acid decarboxylase 65 only Yes, to anti-islet antigen-2 only Yes, to islet-cell autoantibody only Yes, to islet-cell autoantibody only Yes, to micro insulin only Yes, to anti-zinc transporter 8 only Yes, to 2 (or more) of the autoantibodies No							
(if 2 or more) Please specify which autoantibodies were present on at least two separate occasions.							
Has the patient had an A1C 5.7-6 to less than 6.5% in the preceding 2 months?	🗌 Yes 🗌 No						
(if no) Does the patient have an oral glucose tolerance test (OGTT) that shows fasting plasma glucose level greater that equal to 100 and less than 126 mg/dL? ☐ Yes ☐							
(if no) Does the patient have an oral glucose tolerance test (OGTT) that shows a two-hour postpranglucose level greater than or equal to 140 and less than 200 mg/dL?	ndial plasma ☐ Yes						
(if no) Did the patient have an oral glucose tolerance test (OGTT) that shows an intervening glucose level at 30, 60 or 90 minutes greater than 200 mg/dL?	ng postprandial Yes INo						
(if no) Has the patient had an intravenous glucose tolerance test (IVGTT)?	🗌 Yes 🗌 No						
(if yes) During the IVGTT, did the results of acute first phase insulin res demonstrate a rise in serum insulin below the first percentile of normal o minutes after the IV glucose challenge?							
Does the patient already have stage 3 type 1 diabetes mellitus (clinical symptoms, receiving treatment, failed OGTT)	? 🗌 Yes 🗌 No						
Does the patient have adequate hematologic function?	🗌 Yes 🗌 No						
(if yes) Does the patient have adequate hepatic function?	🗌 Yes 🗌 No						
(if yes) Does the patient have evidence of acute infection with Epstein-Barr Virus or cytomegaloviru	ıs? □Yes □No						
(if no) Does the patient have evidence of an active serious infection?							
Has the patient ever been treated with Tzield before this request?	🗌 Yes 🗌 No						
Is the requested medication being prescribed by an endocrinologist?	🗌 Yes 🗌 No						
Please provide any additional pertinent clinical information, including: if the patient is currently on the requested drug use) and how they have been receiving it (samples, out of pocket, etc).	(with dates of						
Additional Information (including prior therapy, disease stage, performance status, and names/doses/admin schede to be used concurrently):	ule of any agents						
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that th insurer its designees may perform a routine audit and request the medical information necessary to verify the accurate information reported on this form.							
Prescriber Signature: Date: Date:							
Save Time! Submit Online at: <u>www.covermymeds.com/main/prior-authorization-forms/cigna/</u> or via SureScription drug coverage requests is 5 business days. If your request is urgent if							
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it your call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cign							
	v041524						

V0415 "Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005